دورية أكاديمية
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
| العنوان: | Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 |
|---|---|
| المؤلفون: | Zhu, Zhen, Lu, Zhaohui, Xu, Tianmin, Chen, Cong, Yang, Gang, Zha, Tao, Lu, Jianchun, Xue, Yuan |
| المصدر: | Journal of Infection |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2020 |
| المجموعة: | Repositório Institucional da Universidade Federal de Lavras (RIUFLA) |
| مصطلحات موضوعية: | COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Ct value, Antiviral therapy, Pneumonia |
| الوصف: | Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including lopinavir/ritonavir group (34 cases) and arbidol group (16 cases). Lopinavir/ritonavir group received 400 mg/100mg of Lopinavir/ritonavir, twice a day for a week, while the arbidol group was given 0.2 g arbidol, three times a day. Data from these patients were retrospectively analyzed. The cycle threshold values of open reading frame 1ab and nucleocapsid genes by RT-PCR assay were monitored during antiviral therapy. None of the patients developed severe pneumonia or ARDS. There was no difference in fever duration between the two groups (P=0.61). On day 14 after the admission, no viral load was detected in arbidol group, but the viral load was found in 15(44.1%) patients treated with lopinavir/ritonavir. Patients in the arbidol group had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group (P<0.01). Moreover, no apparent side effects were found in both groups. In conclusion, our data indicate that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | ZHU, Z. et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. Journal of Infection, [S.l.], v. 81, n. 1, p. e21-e23, July 2020.; https://www.sciencedirect.com/science/article/pii/S0163445320301882Test; http://repositorio.ufla.br/jspui/handle/1/41665Test |
| الإتاحة: | http://repositorio.ufla.br/jspui/handle/1/41665Test https://www.sciencedirect.com/science/article/pii/S0163445320301882Test |
| حقوق: | restrictAccess |
| رقم الانضمام: | edsbas.3A17F919 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |